{"id":"truvada-raltegravir","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Renal impairment (with tenofovir)"},{"rate":null,"effect":"Bone density loss"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TRUVADA is a fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate, both nucleoside reverse transcriptase inhibitors that block the enzyme HIV uses to convert its RNA genome into DNA. Raltegravir is an integrase strand transfer inhibitor that prevents the viral DNA from integrating into the host cell's chromosome. Together, they provide dual mechanisms to suppress viral replication.","oneSentence":"This combination blocks HIV replication by inhibiting reverse transcriptase (TRUVADA) and integrase (raltegravir), preventing the virus from copying itself and integrating into host DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:35:41.676Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection treatment"},{"name":"HIV-1 pre-exposure prophylaxis (PrEP) when combined with raltegravir"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT01234116","phase":"PHASE4","title":"Post-Exposure Prophylaxis in Health Care Workers","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2011-02","conditions":"Human Immunodeficiency Virus","enrollment":16},{"nctId":"NCT07080138","phase":"","title":"Research on the Psychological Status of Patients With HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-01","conditions":"HIV-1-infection, Anxiety Depression","enrollment":500},{"nctId":"NCT02285114","phase":"PHASE2, PHASE3","title":"Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-20","conditions":"HIV-1","enrollment":41},{"nctId":"NCT04442737","phase":"PHASE4","title":"A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2020-07-01","conditions":"HIV-1","enrollment":103},{"nctId":"NCT03954327","phase":"PHASE2","title":"Combination Antiretroviral Therapy (cART) for PBC","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2021-03-01","conditions":"Primary Biliary Cholangitis","enrollment":37},{"nctId":"NCT02336074","phase":"PHASE2","title":"Research In Viral Eradication of HIV Reservoirs","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2015-11-27","conditions":"HIV","enrollment":60},{"nctId":"NCT05648201","phase":"PHASE4","title":"Study on PhArmacokinetics of First liNe Antiretrovirals in Healthy Breastfeeding Volunteers","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2023-03-01","conditions":"Hiv","enrollment":36},{"nctId":"NCT00594646","phase":"PHASE4","title":"HIV Non Occupational Post-Exposure Prophylaxis (PEP)","status":"COMPLETED","sponsor":"Fenway Community Health","startDate":"2008-02","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT00660972","phase":"PHASE1","title":"Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-05","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT00852618","phase":"","title":"Intensive Viral Dynamics Substudy of A5248","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-05","conditions":"HIV Infections, Treatment Naive","enrollment":11},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT01147107","phase":"PHASE4","title":"Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection","status":"COMPLETED","sponsor":"University of Hawaii","startDate":"2014-02","conditions":"Hepatitis C, Chronic, HIV Infection","enrollment":80},{"nctId":"NCT01352715","phase":"PHASE3","title":"Study of Options for Second-Line Effective Combination Therapy (SELECT)","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-03-13","conditions":"HIV-1 Infection","enrollment":515},{"nctId":"NCT02577042","phase":"PHASE4","title":"Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2015-10-15","conditions":"Aging-related Inflammation in HIV-infected Patients","enrollment":42},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT00752856","phase":"PHASE2","title":"Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-08-26","conditions":"HIV Infections","enrollment":51},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT01641367","phase":"PHASE4","title":"A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-02-22","conditions":"HIV-1 Infection","enrollment":545},{"nctId":"NCT02131233","phase":"PHASE3","title":"Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-23","conditions":"HIV Infection","enrollment":802},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT01902186","phase":"PHASE4","title":"Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir","status":"TERMINATED","sponsor":"Giovanni Di Perri","startDate":"2014-09","conditions":"HIV Infection, Osteopenia","enrollment":4},{"nctId":"NCT00632970","phase":"PHASE4","title":"Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals","status":"TERMINATED","sponsor":"George Washington University","startDate":"2008-02","conditions":"HIV Infections","enrollment":6},{"nctId":"NCT01605890","phase":"PHASE2","title":"Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2012-07","conditions":"HIV-2 Infection","enrollment":30},{"nctId":"NCT01450189","phase":"NA","title":"A Key Link for Transmission Prevention","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2011-10","conditions":"HIV","enrollment":46},{"nctId":"NCT01978743","phase":"NA","title":"Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-01","conditions":"HIV, HIV-associated Neurocognitive Disorder, Neurotoxicity","enrollment":10},{"nctId":"NCT00931801","phase":"PHASE4","title":"BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2009-12","conditions":"HIV","enrollment":43},{"nctId":"NCT02449733","phase":"NA","title":"Comprehensive HIV Prevention Package for MSM in Port Elizabeth","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-05","conditions":"HIV","enrollment":101},{"nctId":"NCT02351908","phase":"PHASE4","title":"Renal Integrase Study","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2015-03","conditions":"HIV","enrollment":60},{"nctId":"NCT01173510","phase":"PHASE4","title":"A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells","status":"WITHDRAWN","sponsor":"Community Research Initiative of New England","startDate":"2010-08-23","conditions":"HIV Infections, Acquired Immune Deficiency Syndrome","enrollment":""},{"nctId":"NCT00369941","phase":"PHASE3","title":"A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-08","conditions":"HIV Infections","enrollment":566},{"nctId":"NCT00745823","phase":"PHASE3","title":"A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09","conditions":"HIV","enrollment":775},{"nctId":"NCT00667433","phase":"PHASE1","title":"Raltegravir as Early Therapy in African-Americans Living With HIV Study","status":"COMPLETED","sponsor":"David A Wohl, MD","startDate":"2008-06","conditions":"HIV Infections","enrollment":38},{"nctId":"NCT01114425","phase":"PHASE3","title":"Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection","status":"COMPLETED","sponsor":"Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux","startDate":"2010-11-01","conditions":"HIV Infections","enrollment":149},{"nctId":"NCT01829802","phase":"PHASE4","title":"RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients","status":"UNKNOWN","sponsor":"Pedro Cahn","startDate":"2014-05","conditions":"Chronic Infection With HIV","enrollment":50},{"nctId":"NCT01285050","phase":"PHASE4","title":"Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2011-01","conditions":"HIV Infection, Hepatitis C","enrollment":20},{"nctId":"NCT00734344","phase":"NA","title":"Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2008-09","conditions":"Acute HIV Infection","enrollment":18},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT01154673","phase":"PHASE2, PHASE3","title":"Effects of Intensive cART During Acute/Early HIV Infection","status":"COMPLETED","sponsor":"University of Toronto","startDate":"2011-11","conditions":"Acute HIV Infection","enrollment":32},{"nctId":"NCT01214759","phase":"PHASE4","title":"Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2011-05","conditions":"HIV","enrollment":103},{"nctId":"NCT00851799","phase":"","title":"Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-06","conditions":"HIV Infection","enrollment":334},{"nctId":"NCT01291459","phase":"PHASE2","title":"Pilot Study of Maraviroc/Raltegravir for Naive HIV-1 Patients","status":"UNKNOWN","sponsor":"Association Pour la Recherche en Infectiologie","startDate":"2011-09","conditions":"HIV","enrollment":40},{"nctId":"NCT00654147","phase":"PHASE2","title":"Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects","status":"COMPLETED","sponsor":"Margaret A. Fischl, M.D.","startDate":"2008-04","conditions":"HIV Infections","enrollment":44},{"nctId":"NCT00863668","phase":"NA","title":"Raltegravir Activity In Lymphoid Tissues","status":"WITHDRAWN","sponsor":"University of Minnesota","startDate":"2009-03","conditions":"HIV Infection, HIV Infections","enrollment":""},{"nctId":"NCT01044771","phase":"NA","title":"Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria","status":"COMPLETED","sponsor":"Metropolis Medical","startDate":"2010-01","conditions":"HIV Infections, Proteinuria","enrollment":20},{"nctId":"NCT00984152","phase":"PHASE3","title":"Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2011-06","conditions":"HIV-1 Infections","enrollment":""},{"nctId":"NCT00785967","phase":"PHASE3","title":"Immune Responses in Patients Treated With Raltegravir","status":"WITHDRAWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2009-01","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT01294761","phase":"NA","title":"Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir","status":"COMPLETED","sponsor":"National Center for Global Health and Medicine, Japan","startDate":"2011-02","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT00525733","phase":"NA","title":"Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"2007-10","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT01332227","phase":"PHASE4","title":"Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-10","conditions":"HIV, Combination Therapy","enrollment":132},{"nctId":"NCT01533259","phase":"PHASE3","title":"Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-01","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":48},{"nctId":"NCT01258439","phase":"PHASE4","title":"Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.","status":"COMPLETED","sponsor":"St Vincent's Hospital, Sydney","startDate":"2010-11","conditions":"HIV, Cardiovascular Disease","enrollment":25},{"nctId":"NCT00762892","phase":"PHASE4","title":"Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2009-01","conditions":"HIV Infections","enrollment":33},{"nctId":"NCT01195467","phase":"PHASE3","title":"Atripla to Raltegravir Switch Study for CNS Toxicity","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2010-10","conditions":"HIV Infection","enrollment":40},{"nctId":"NCT01565889","phase":"PHASE1, PHASE2","title":"Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-03","conditions":"Hepatitis C, HIV","enrollment":52},{"nctId":"NCT00677300","phase":"PHASE4","title":"Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients","status":"COMPLETED","sponsor":"Dallas VA Medical Center","startDate":"2009-01","conditions":"HIV Infections","enrollment":85},{"nctId":"NCT00811954","phase":"PHASE3","title":"Comparative Study of Three NNRTI-Sparing HAART Regimens","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-05","conditions":"HIV Infection","enrollment":1814},{"nctId":"NCT00624195","phase":"PHASE2, PHASE3","title":"Clinical Trial of CNS-targeted HAART (CIT2)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2007-03","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT01087840","phase":"PHASE4","title":"Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men","status":"COMPLETED","sponsor":"Andrew Carr","startDate":"2010-07","conditions":"HIV Prevention, HIV Infections","enrollment":120},{"nctId":"NCT01033760","phase":"PHASE3","title":"Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2010-04","conditions":"HIV-1 Infections","enrollment":90},{"nctId":"NCT01270802","phase":"PHASE4","title":"Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients","status":"COMPLETED","sponsor":"Indiana University","startDate":"2011-04","conditions":"HIV","enrollment":30},{"nctId":"NCT01697046","phase":"PHASE3","title":"A Pilot Study on Raltegravir, Tenofovir and Emtricitabine for Peri-exposure Prophylaxis for HIV Infection","status":"UNKNOWN","sponsor":"Projeto Praça Onze","startDate":"2012-11","conditions":"Infection, HIV","enrollment":65},{"nctId":"NCT00768989","phase":"PHASE2","title":"Phase IIB Pilot of Atazanavir + Raltegravir","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2008-11","conditions":"HIV","enrollment":167},{"nctId":"NCT00711009","phase":"PHASE3","title":"Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-07","conditions":"Human Immunodeficiency Virus Infection","enrollment":206},{"nctId":"NCT01343225","phase":"PHASE4","title":"Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection","status":"UNKNOWN","sponsor":"East Carolina University","startDate":"2011-05","conditions":"HIV","enrollment":40},{"nctId":"NCT01066065","phase":"","title":"Metabolic Safety of Raltegravir Versus Darunavir in HIV Naive Patients","status":"UNKNOWN","sponsor":"Hospital Carlos III, Madrid","startDate":"2010-02","conditions":"Cardiovascular Disease, HIV Infections","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":441,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["tenofovir DF","emtricitabine"],"phase":"marketed","status":"active","brandName":"TRUVADA + Raltegravir","genericName":"TRUVADA + Raltegravir","companyName":"Fenway Community Health","companyId":"fenway-community-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination blocks HIV replication by inhibiting reverse transcriptase (TRUVADA) and integrase (raltegravir), preventing the virus from copying itself and integrating into host DNA. Used for HIV-1 infection treatment, HIV-1 pre-exposure prophylaxis (PrEP) when combined with raltegravir.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}